Loading stock data…
CRBP
$10.30+0.42 (+4.25%)
Market ClosedLast close May 1
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Corbus Pharmaceuticals Holdings, Inc. in the Healthcare sector is trading at $10.30. The stock is currently 50% below its 52-week high of $20.56, remaining 0.6% above its 200-day moving average. Technical signals show neutral RSI of 52 and bearish MACD signal, explaining why CRBP maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 52) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$10.30
Potential Upside
5%
Whystock Fair Value$10.82
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Mean target$41.67+304.5%
Range$28.00 – $57.00
Fundamentals
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to rel...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$185.88M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.79
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-53.24%
Volume
Today's trading volume
531,160
Recent News
Spotify upgraded, Alibaba initiated: Wall Street's top analyst calls
Spotify upgraded, Alibaba initiated: Wall Street's top analyst calls
Mizuho Sees Strong Risk-Reward in Corbus Pharmaceuticals Holdings, Inc. (CRBP) Near Cash Value
We recently compiled a list of the 10 Best Biotech Stocks Under $10 to Buy. Corbus Pharmaceuticals Holdings, Inc. is among the best biotech stocks. TheFly reported on April 7 that Mizuho raised its price target on CRBP from $39 to $40 while maintaining an Outperform rating. The firm updated its valuation model following the […]
How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33%
The mean of analysts' price targets for Corbus Pharmaceuticals (CRBP) points to a 318.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Corbus Pharmaceuticals: Q4 Earnings Snapshot
NORWOOD, Mass. AP) — Corbus Pharmaceuticals Holdings Inc. CRBP) on Monday reported a loss of $20.6 million in its fourth quarter.
Corbus Pharmaceuticals Touts “Catalyst-Rich” 2026 With CRB-701 and CRB-913 Data Readouts Ahead
Corbus Pharmaceuticals (NASDAQ:CRBP) outlined a “catalyst-rich” 2026 at Oppenheimer’s 36th Annual Healthcare Conference, with Chief Executive Officer Yuval Cohen highlighting upcoming mid-year and late-year data readouts for the company’s two clinical-stage programs: CRB-701, a Nectin-4 antibody-dru